ÂÜÀòÂÒÂ×

Dr. Hongjun Yang currently serves as an SVP of Companion Diagnostics at DiaCarta, Inc. Dr. Yang is a well-established, passionate and dynamic executive in the biomedical and pharmaceutical industry and academia with a diversified multidisciplinary background and extensive experience in Research and Development management, technology innovation, corporate development, global business development and collaboration, long-term strategic planning, quality management system (QMS), clinical trial operation (IND, CTP, HGR), and compliance with the regulations (CLIA, CAP, GXP), chemical manufacturing control (CMC), commercialization and product launching in diagnostics, therapeutics, biopharmaceutical industries and specialized in precision medicine, biomarkers & diagnostics, public health, etc.

Dr. Yang has been served as an executive at multiple startup companies and institutes in both US and China. He was the original developer of electrochemiluminescence (ECL) technology and its instrumentation which is exclusively owned by Roche diagnostics. He is a pioneer for flow-thru DNA chip technology, an initiator of the global human genome HapMap program, gene expression database, NGS platform design, biomarkers, and companion diagnostics for precision medicine. Dr. Yang also initiated the growth and development of Zhangjiang Biopharma Park, Shanghai, China as well as the promotion for the international collaborations between China and West Countries. Prior to the current post, Dr. Yang served as a director of personalized Healthcare and biomarkers at AstraZeneca-China, then was promoted as an executive personalized healthcare strategy leader at AstraZeneca-Global due to his outstanding performance and delivery. Recently he joined DiaCarta as SVP of companion diagnostics and he is focused on the next generation of companion diagnostics to facilitate anti-cancer drug discovery and development, and the implementation of precision medicine.